

CHLD0071: Molecular and Clinical Aspects of Childhood Cancers

View Online



-
1.
Weinberg, R. A. The biology of cancer. (Garland Science, 2014).

 2.
Hanahan, D. & Weinberg, R. A. The Hallmarks of Cancer. *Cell* **100**, 57–70 (2000).

 3.
Hanahan, D. & Weinberg, R. A. Hallmarks of Cancer: The Next Generation. *Cell* **144**, 646–674 (2011).

 4.
Lord, C. J. & Ashworth, A. Biology-driven cancer drug development: back to the future. *BMC Biology* **8**, (2010).

 5.
Vogelstein, B. et al. Cancer Genome Landscapes. *Science* **339**, 1546–1558 (2013).

 6.
Lee, T. I. & Young, R. A. Transcriptional Regulation and Its Misregulation in Disease. *Cell* **152**, 1237–1251 (2013).

7.

Children's cancer statistics | Cancer Research UK.

<http://www.cancerresearchuk.org/health-professional/cancer-statistics/childrens-cancers>.

8.

International Agency for Research on Cancer. WHO classification of tumours of the central nervous system. (International Agency for Research on Cancer, 2016).

9.

Taylor, Michael D Northcott, Paul A Korshunov, Andrey Remke, Marc Cho, Yoon-jae. Molecular subgroups of medulloblastoma: the current consensus. *Acta Neuropathologica* **123**, 465–72.

10.

Gibson, P. et al. Subtypes of medulloblastoma have distinct developmental origins. *Nature* **468**, 1095–1099 (2010).

11.

Ellison, D. W. et al. β -Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. *Journal of Clinical Oncology* **23**, 7951–7957 (2005).

12.

Nataliya Zhukova. Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. *Journal of Clinical Oncology* **31**, (2013).

13.

Stone, T. J. & Jacques, T. S. Medulloblastoma: selecting children for reduced treatment. *Neuropathology and Applied Neurobiology* **41**, 106–108 (2015).

14.

Schwalbe, E. C. et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. *The Lancet Oncology* **18**, 958–971 (2017).

15.

Pfister, S. et al. Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. *Acta Neuropathologica* **117**, 457–464 (2009).

16.

Korshunov, Andrey Sturm, Dominik Ryzhova, Marina Hovestadt, Volker Gessi, Marco. Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. *Acta Neuropathologica* **128**, 279–89.

17.

Schwalbe, Ed. C. et al. Histologically defined central nervous system primitive neuro-ectodermal tumours (CNS-PNETs) display heterogeneous DNA methylation profiles and show relationships to other paediatric brain tumour types. *Acta Neuropathologica* **126**, 943–946 (2013).

18.

Sturm, D. et al. New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. *Cell* **164**, 1060–1072 (2016).

19.

Kirsti Sirkiä, Ulla M. Saarinen-Pihkala, Liisa Hovi, Hannu Sariola. Autopsy in children with cancer who die while in terminal care. *Medical and Pediatric Oncology* **30**, 284–289 (1998).

20.

Buckner, T., Blatt, J. & Smith, S. V. The Autopsy in Pediatrics and Pediatric Oncology: A Single-Institution Experience. *Pediatric and Developmental Pathology* **9**, 374–380 (2006).

21.

Bleggi-Torres, L. F. et al. Accuracy of the smear technique in the cytological diagnosis of 650 lesions of the central nervous system. *Diagnostic Cytopathology* **24**, 293–295 (2001).

22.

Hill, R. M. et al. Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease. *Cancer Cell* **27**, 72–84 (2015).

23.

Blümcke, I. et al. Low-grade epilepsy-associated neuroepithelial tumours — the 2016 WHO classification. *Nature Reviews Neurology* **12**, 732–740 (2016).

24.

Chhabda, S., Carney, O., D'Arco, F., Jacques, T. S. & Mankad, K. The 2016 World Health Organization Classification of tumours of the Central Nervous System: what the paediatric neuroradiologist needs to know. *Quantitative Imaging in Medicine and Surgery* **6**, 486–489 (2016).

25.

Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. *Nature* **482**, 226–231 (2012).

26.

Sturm, D. et al. Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. *Cancer Cell* **22**, 425–437 (2012).

27.

Lewis, P. W. et al. Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma. *Science* **340**, 857–861 (2013).

28.

Bender, S. et al. Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. *Cancer Cell* **24**, 660–672 (2013).

29.

Hashizume, R. et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. *Nature Medicine* **20**, 1394–1396 (2014).

30.

Pathania, M. et al. H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas. *Cancer Cell* **32**, 684–700.e9 (2017).

31.

Larson, J. D. et al. Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression. *Cancer Cell* (2018)
doi:10.1016/j.ccell.2018.11.015.

32.

Martinez-Barbera, J. P. & Andoniadou, C. L. Concise Review: Paracrine Role of Stem Cells in Pituitary Tumors: A Focus on Adamantinomatous Craniopharyngioma. *STEM CELLS* **34**, 268–276 (2016).

33.

Gump, J. M. et al. Identification of targets for rational pharmacological therapy in childhood craniopharyngioma. *Acta Neuropathologica Communications* **3**, (2015).

34.

Martinez-Barbera, J. P. & Buslei, R. Adamantinomatous craniopharyngioma: pathology, molecular genetics and mouse models. *Journal of Pediatric Endocrinology and Metabolism* **28**, (2015).

35.

Goschzik, T. et al. Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma. *Journal of Neuropathology & Experimental Neurology* (2017) doi:10.1093/jnen/nlw116.

36.

Azarova, A. M., Gautam, G. & George, R. E. Emerging importance of ALK in neuroblastoma. *Seminars in Cancer Biology* **21**, 267–275 (2011).

37.

Beierle, E. A. MYCN, Neuroblastoma and Focal Adhesion Kinase (FAK). *Frontiers in bioscience (Elite edition)* **3**,.

38.

Bell, E. et al. MYCN oncoprotein targets and their therapeutic potential. *Cancer Letters* **293**, 144–157 (2010).

39.

Berry, T. et al. The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma. *Cancer Cell* **22**, 117–130 (2012).

40.

Brodeur, G. M. Neuroblastoma: biological insights into a clinical enigma. *Nature Reviews Cancer* **3**, 203–216 (2003).

41.

Brodeur, G. M. & Bagatell, R. Mechanisms of neuroblastoma regression. *Nature Reviews Clinical Oncology* **11**, 704–713 (2014).

42.

Garrett M. Brodeur, Robert C. Seeger, Manfred Schwab, Harold E. Varmus and J. Michael Bishop. Amplification of N-myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage. *Science* **224**, 1121–1124 (1984).

43.

Burkhart, C. A. et al. Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma. *JNCI Journal of the National Cancer Institute* **95**, 1394–1403 (2003).

44.

Chen, L. et al. p53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma. *Cancer Research* **70**, 1377–1388 (2010).

45.

Cossu, I. et al. Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion. *Biomaterials* **68**, 89–99 (2015).

46.

Evans, A. E., Baum, E. & Chard, R. Do infants with stage IV-S neuroblastoma need treatment? *Archives of Disease in Childhood* **56**, 271–274 (1981).

47.

Guglielmi, L. et al. MYCN gene expression is required for the onset of the differentiation programme in neuroblastoma cells. *Cell Death & Disease* **5**, e1081–e1081 (2014).

48.

Huang, M. & Weiss, W. A. Neuroblastoma and MYCN. Cold Spring Harbor Perspectives in Medicine **3**, a014415–a014415 (2013).

49.

Huber, K., Kalcheim, C. & Unsicker, K. The development of the chromaffin cell lineage from the neural crest. Autonomic Neuroscience **151**, 10–16 (2009).

50.

Liu, Z. & Thiele, C. J. ALK and MYCN: When Two Oncogenes Are Better than One. Cancer Cell **21**, 325–326 (2012).

51.

Marabelle, A. et al. Hypercalcemia and 13-
-retinoic acid in
post-consolidation therapy of neuroblastoma. Pediatric Blood & Cancer **52**, 280–283 (2009).

52.

Matthay, K. K. et al. Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-
-Retinoic Acid. New England Journal of Medicine **341**, 1165–1173 (1999).

53.

Mossé, Y. P. et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature **455**, 930–935 (2008).

54.

Pastorino, F. et al. Ligand-Targeted Liposomal Therapies of Neuroblastoma. Current Medicinal Chemistry **14**, 3070–3078 (2007).

55.

Qiao, J. et al. PI3K/AKT and ERK regulate retinoic acid-induced neuroblastoma cellular differentiation. *Biochemical and Biophysical Research Communications* **424**, 421–426 (2012).

56.

Reynolds, C. P., Matthay, K. K., Villablanca, J. G. & Maurer, B. J. Retinoid therapy of high-risk neuroblastoma. *Cancer Letters* **197**, 185–192 (2003).

57.

Schwab, M. MYCN in neuronal tumours. *Cancer Letters* **204**, 179–187 (2004).

58.

Sidell, N. Retinoic Acid-Induced Growth Inhibition and Morphologic Differentiation of Human Neuroblastoma Cells In Vitro. *JNCI: Journal of the National Cancer Institute* (1982) doi:10.1093/jnci/68.4.589.

59.

Vogelstein, B. et al. Cancer Genome Landscapes. *Science* **339**, 1546–1558 (2013).

60.

Wright, J. H. NEUROCYTOMA OR NEUROBLASTOMA, A KIND OF TUMOR NOT GENERALLY RECOGNIZED. *The Journal of Experimental Medicine* **12**, (1910).

61.

Yang, LiqunKe, Xiao-XueXuan, FanTan, JuanHou, Jianbing. PHOX2B Is Associated with Neuroblastoma Cell Differentiation. *Cancer Biotherapy & Radiopharmaceuticals* **31**, 44–51.

62.

Zhu, S. et al. Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis. *Cancer Cell* **21**, 362–373 (2012).

63.

Hasle, H. & Niemeyer, C. M. Advances in the prognostication and management of advanced MDS in children. *British Journal of Haematology* **154**, 185–195 (2011).

64.

Niemeyer, C. M. & Kratz, C. P. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. *British Journal of Haematology* **140**, 610–624 (2008).

65.

Wegman-Ostrosky, T. & Savage, S. A. The genomics of inherited bone marrow failure: from mechanism to the clinic. *British Journal of Haematology* **177**, 526–542 (2017).

66.

Strebhardt, K. & Ullrich, A. Paul Ehrlich's magic bullet concept: 100 years of progress. *Nature Reviews Cancer* **8**, 473–480 (2008).

67.

Koebel, C. M. et al. Adaptive immunity maintains occult cancer in an equilibrium state. *Nature* **450**, 903–907 (2007).

68.

Mackall, C. L., Merchant, M. S. & Fry, T. J. Immune-based therapies for childhood cancer. *Nature Reviews Clinical Oncology* **11**, 693–703 (2014).

69.

Klebanoff, C. A., Rosenberg, S. A. & Restifo, N. P. Prospects for gene-engineered T cell immunotherapy for solid cancers. *Nature Medicine* **22**, 26–36 (2016).

70.

Nature Reviews Immunology. **12**, (2012).

71.

Majzner, R. G., Heitzeneder, S. & Mackall, C. L. Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. *Cancer Cell* **31**, 476–485 (2017).

72.

Greaves, M. F. & Wiemels, J. Origins of chromosome translocations in childhood leukaemia. *Nature Reviews Cancer* **3**, 639–649 (2003).

73.

Zelent, A., Greaves, M. & Enver, T. Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. *Oncogene* **23**, 4275–4283 (2004).

74.

Slany, R. K. The molecular mechanics of mixed lineage leukemia. *Oncogene* **35**, 5215–5223 (2016).

75.

Milne, T. A. Mouse models of MLL leukemia: recapitulating the human disease. *Blood* **129**, 2217–2223 (2017).

76.

Sadelain, M., Rivière, I. & Riddell, S. Therapeutic T cell engineering. *Nature* **545**, 423–431 (2017).

77.

Johnson, L. A. & June, C. H. Driving gene-engineered T cell immunotherapy of cancer. *Cell Research* **27**, 38–58 (2017).

78.

Yong, C. S. M. et al. CAR T-cell therapy of solid tumors. *Immunology and Cell Biology* **95**, 356–363 (2017).

79.

Fisher, J. et al. Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor. *Molecular Therapy* **25**, 1234–1247 (2017).

80.

Brown, C. E. et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. *New England Journal of Medicine* **375**, 2561–2569 (2016).

81.

Morsut, L. et al. Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. *Cell* **164**, 780–791 (2016).

82.

Rasaiyaah, J., Georgiadis, C., Preece, R., Mock, U. & Qasim, W. TCR $\alpha\beta$ /CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. *JCI Insight* **3**, (2018).

83.

Ghorashian, S., Amrolia, P. & Veys, P. Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL. *Experimental Hematology* **66**, 5–16 (2018).

84.

Qasim, W. et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. *Science Translational Medicine* **9**, (2017).

85.

Hubert, C. G. et al. A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found. *Cancer Research* **76**, 2465–2477 (2016).

86.

Richmond, A. & Su, Y. Mouse xenograft models vs GEM models for human cancer therapeutics. *Disease Models and Mechanisms* **1**, 78–82 (2008).

87.

Phoenix, T. N. et al. Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. *Cancer Cell* **29**, 508–522 (2016).

88.

Lu, B., Green, B., Farr, J., Lopes, F. & Van Raay, T. Wnt Drug Discovery: Weaving Through the Screens, Patents and Clinical Trials. *Cancers* **8**, (2016).

89.

Northcott, P. A., Korshunov, A., Pfister, S. M. & Taylor, M. D. The clinical implications of medulloblastoma subgroups. *Nature Reviews Neurology* **8**, 340–351 (2012).

90.

Niklison-Chirou, M. V. et al. TAp73 is a marker of glutamine addiction in medulloblastoma. *Genes & Development* **31**, 1738–1753 (2017).

91.

Hourigan, C. S. & Karp, J. E. Minimal residual disease in acute myeloid leukaemia. *Nature Reviews Clinical Oncology* **10**, 460–471 (2013).

92.

Kotrova, M., Trka, J., Kneba, M. & Brüggemann, M. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia? *Molecular Diagnosis & Therapy* **21**, 481–492 (2017).

93.

O'Connor, D. et al. Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology* **36**, 34–43 (2018).

94.

Vora, A. et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. *The Lancet Oncology* **14**, 199–209 (2013).

95.

Vora, A. et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. *The Lancet Oncology* **15**, 809–818 (2014).

96.

Hunger, S. P. & Mullighan, C. G. Acute Lymphoblastic Leukemia in Children. *New England Journal of Medicine* **373**, 1541–1552 (2015).

97.

O'Connor, D. et al. Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology* **36**, 34–43 (2018).